keloid. Hypertrophic scar
Conditions
Interventions
Intervention 1: Control group: Patients in the control group will receive intralesional injections of 5-fluorouracil 0.2 cc from vials of 5-fluorouracil 250mg/5ml and triamcinolone 10 mg in 3 sessions
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with keloid lesions based on clinical diagnosis or pathology who have not received any other treatments for at least 6 months prior to or at the same time as initiating treatment.
Exclusion criteria
Exclusion criteria: Patients with coagulation disorders or hematologic disorders such as hemophilia. Patients taking blood-thinning drugs such as aspirin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Keloid lesion diameter. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Using a ruler and Vancouver scar scale.;Height of keloid lesion. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Using a ruler and Vancouver scar scale.;Keloid lesion color. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observe in natural light and Vancouver scar scale.;Pain. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Asking patient about pain in the lesion.;Consistency. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observing and touching the lesion and Vancouver scar scale.;Itching. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Asking patient about presence of itching in the lesion.;Skin atrophy. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observing the lesion.;Telangiectasia. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observing the lesion in terms of the appearance of arteries as fine red lines on the skin.;Hypopigmentation and hyperpigmentation. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observing the lesion in terms of decrease or increase of skin pigments and Vancouver scar scale.;Ulcer. Timepoint: Before treatment, end of treatment and 2 months after the end of treatment. Method of measurement: Observing the lesion in terms of presence of ulcers. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Sima
Tehran University of Medical Sciences
Outcome results
None listed